Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | CYP19A1 | P11511 | 9/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.39 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8661015 | 1.00 | LMNA (0.44) | LMNAMAPTCYP19A1NR3C1CYP3A4 | |
| SCHEMBL6521590 | 1.00 | LMNA (0.44) | LMNAMAPTCYP19A1NR3C1CYP3A4 | |
| SCHEMBL6676011 | 0.93 | LMNA (0.45) | LMNAMAPTCYP19A1NR3C1CYP3A4 | |
| SCHEMBL8695467 | 0.90 | LMNA (0.43) | LMNAMAPTCYP19A1NR3C1CYP3A4 | |
| SCHEMBL7877720 | 0.86 | LMNA (0.52) | LMNAMAPTCYP19A1NR3C1CYP3A4 | |
| SCHEMBL5672145 | 0.86 | LMNA (0.52) | LMNAMAPTCYP19A1NR3C1CYP3A4 | |
| SCHEMBL3396581 | 0.83 | LMNA (0.51) | LMNAMAPTCYP19A1NR3C1CYP3A4 | |
| SCHEMBL15994233 | 0.83 | LMNA (0.51) | LMNAMAPTCYP19A1NR3C1CYP3A4 | |
| SCHEMBL6888641 | 0.81 | CYP19A1 (0.36) | LMNAMAPTCYP19A1NR3C1CYP3A4 | |
| SCHEMBL6036866 | 0.81 | CYP19A1 (0.36) | LMNAMAPTCYP19A1NR3C1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2007500233-A | — | — | 2007-01-11 | — | — | JP | claimed |
| EP-1706371-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2006-10-04 | — | — | EP | claimed |
| EP-1641744-A2 | CRYSTALLINE FORM OF B2 ADRENERGIC RECEPTOR AGONIST | Theravance, Inc. (US) | 2006-04-05 | — | — | EP | claimed |
| WO-2005070872-A1 | ARYL ANILINE DERIVATIVES AS BETA2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-08-04 | — | — | WO | claimed |
| WO-2004106279-A2 | CRYSTALLINE FORM OF β2 ADRENERGIC RECEPTOR AGONIST | THERAVANCE, INC. (US) | 2004-12-09 | — | — | WO | claimed |
| EP-2323656-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A BETA-2-ADRENOCEPTOR AGONIST | AstraZeneca AB (SE) | 2011-05-25 | — | — | EP | disclosed |
| EP-2249646-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-17 | — | — | EP | disclosed |
| EP-2249647-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-17 | — | — | EP | disclosed |
| EP-2249830-A1 | DUAL PHARMACOPHORES - PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-17 | — | — | EP | disclosed |
| EP-2247184-A1 | DUAL PHARMACOPHORES-PDE4-MUSCARINIC ANTAGONISTICS | Glaxo Group Limited (GB) | 2010-11-10 | — | — | EP | disclosed |
| WO-2010074219-A1 | BENZOTHIOPHEN COMPOUND | アステラス製薬株式会社 (JP) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010071581-A1 | PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A B2-ADRENOCEPTOR AGONIST | ASTRAZENECA AB (SE) | 2010-06-24 | — | — | WO | disclosed |
| WO-2009001132-A1 | PYRAZINONE DERIVATIVES AND THEIR USE IN THE TREATMENT OF LUNG DISEASES | ASTRAZENECA AB (SE) | 2008-12-31 | — | — | WO | disclosed |
| WO-2007124423-A2 | IL-8 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-11-01 | — | — | WO | disclosed |
| EP-1723142-A1 | DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | Theravance, Inc. (US) | 2006-11-22 | — | — | EP | disclosed |
| WO-2005087763-A1 | DIPHENYLMETHYL COMPOUNDS USEFUL AS MUSCARINIC RECEPTOR ANTAGONISTS | THERAVANCE, INC. (US) | 2005-09-22 | — | — | WO | disclosed |
| EP-1532104-A1 | CRYSTALLINE BETA-2 ADRENERGIC RECEPTOR AGONIST | Theravance, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004011416-A1 | CRYSTALLINE β2 ADRENERGIC RECEPTOR AGONIST | THERAVANCE, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
| EP-1360174-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2003-11-12 | — | — | EP | disclosed |
| WO-2002066422-A1 | PHENETHANOLAMINE DERIVATIVES FOR TREATMENT OF RESPIRATORY DISEASES | GLAXO GROUP LIMITED (GB) | 2002-08-29 | — | — | WO | disclosed |